Daiichi Sankyo gets Japenese nod for Tarlige tablets to treat neuropathic pain

Written by Ruchika Sharma Published On 2022-03-31T09:45:55+05:30 | Updated On 31 March 2022 9:45 AM IST

Daiichi Sankyo gets Japenese nod for Tarlige tablets to treat neuropathic pain

Tokyo: Daiichi Sankyo Company, Limited has announced that the company has obtained approval in Japan to change the indication of the analgesic "Tarlige Tablets" (mirogabalin besilate) from "peripheral neuropathic pain" to "neuropathic pain."

Neuropathic pain is pain caused by lesions or diseases of the somatosensory nervous system and is classified into peripheral neuropathic pain and central neuropathic pain (CNP), according to the anatomical location of the nerve damage site that causes the pain. CNP is pain that arises from central nerve injury or impairment such as spinal cord injury and central post-stroke pain.

In May 2021, Daiichi Sankyo submitted a supplemental new drug application (sNDA) for Tarlige Tablets based on results from a phase 3 trial in patients with CNP.

"By delivering a new therapeutic option for CNP, Daiichi Sankyo hopes to contribute to healthcare of patients," the release stated.

Tarlige is an analgesic proprietarily discovered by Daiichi Sankyo that works by inhibiting excessive release of pain-related neurotransmitters in presynaptic nerve terminal. Tarlige was approved for the indication of "peripheral neuropathic pain" in Japan in January 2019 and was launched in April of the same year.

Read also: Daiichi Sankyo gets approval for additional indication of Antiplatelet Agent Efient in Japan

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. The company was founded in 2005 through the merger of Sankyo Company, Limited and Daiichi Pharmaceutical Company, Limited. It provides innovative products and services in more than 20 countries around the world.

In addition to the company's current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical need.

Read also: Daiichi Sankyo submits NDA for Lymphoma treatment Valemetostat in Japan

daiichi sankyodaiichi sankyo newstarlige tabletsmirogabalin besilateperipheral neuropathic painneuropathic pain

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751